Evidence map›Paper›PMID 40980570›Full record

Trial reportOpen forum infectious diseases2025

Costs of 4 Months of Rifampin Versus 2 Months of Double-dose Rifampin for Tuberculosis Infection: Post-Hoc Analysis of a Phase 2b Randomized Trial.

Kamila Romanowski, Yen Pham Ngoc, Leila Barss, Elias Jabbour, James C Johnston, Hansen Herman, Richard Long, Lika Apriani, Greg Fox, Dick Menzies and 1 more

Abstract readClinical Trial
In one paragraph

Trial report in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kamila RomanowskiDepartment of Global and Public Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0002-7027-3579
Yen Pham NgocVietnam Institute, University of Sydney, Hanoi, Vietnam.ORCID https://orcid.org/0000-0003-1644-4194
Leila BarssDepartment of Medicine, Division of Respirology, University of Calgary, Calgary, Alberta, Canada.
Elias JabbourDepartment of Medicine, McGill University, Montreal, Quebec, Canada.
James C JohnstonTB Services, BC Centre for Disease Control; Division of Respiratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Hansen HermanDepartment of Public Health, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Richard LongDepartment of Medicine, Faculty of Medicine and Dentistry, College of Health Sciences, University of Alberta, Edmonton, Alberta, Canada.
Lika AprianiDepartment of Public Health, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Greg FoxFaculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Dick MenziesDepartment of Medicine & Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0003-1601-4514
Jonathon R CampbellMcGill International TB Centre, Montreal, Quebec, Canada.ORCID https://orcid.org/0000-0003-2341-2166

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cost is an important consideration when implementing tuberculosis preventive treatment regimens (TPT). We used data from a phase 2b randomized trial of TPT to estimate overall cost and key drivers of costs for two TPT regimens. Methods: We did a post-hoc analysis of 915 participants aged ≥10 years who were randomized 1:1 to 2 rifampin-based regimens: a four-month daily regimen at 10 mg/kg (4R Results: Overall, 454 participants received 4R Conclusions: Most costs associated with TPT are due to medications and the baseline treatment initiation visit. TPT regimens requiring fewer follow-up visits may reduce overall cost, but the magnitude of this reduction varies by country.

Indexed as

global healthinfectious diseasepreventionpublic healthtuberculosis

Identifiers

PMID40980570
PMCPMC12449732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.